PTO/SB/25 (01-08)

Approach for use through 613-015 (MSE) TO OBVATE A PROVINCIAN to respond to a collection of information unless this things a visit OBM 100 (MSE).

J. S. Patent and Tablematic Office, U.S. DEPARTMENT OF COMMENCE.

TERMINAL DISCLAIMED TO OBVATE A PROVINCIAN CONTROL OF COMMENCE.

REJECTION OVER A PENDING "REFERENCE" APPLICATION	PC27932A
in re Application of: Nancy J. Britten et al.	
Application No.: 10/803,146	
Filed: March 17, 2004	
For. DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT	
The owner! "Pharmacia & Uplotin Company of 100 percent interest in the lists except as provided below the kernial part of the statutory term of any patent granter on the island analysis the expiration dute of the full statutory term of any patent granted on pending reference Application Number of 1500 percent of 1500	atent granted on said reference reference application. The owner such period that it and any paters
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on it extend to the expresion date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any pa- ospicitation. Fast the term of any patent granted on safe deverence application may be shortened by any term grant of any patent on the pending reference application, in the event that, any such patent granted on the pa- exprise for filture to any an amintenance less, is had unnerforceable, is found invalid by a court of competent just in whose or terminally disclaimed under 37 CPR 1.321, has all claims canceled by a reexamination certificate terminated price to the expression of its oil statisticity erms as shortened by any terminal disclaims filed prior to fit.	dent granted on said reference minal disclaimer filed prior to the ending reference application: isoliction, is statutorily disclaimed is reissued, or is in any manner
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, gover etc.), the undersigned is empowered to act on behalf of the business/organization. 	nment agency,
I hereby declare that all statements made herein of my own knowledge are true and that all state belief are believed to be true: and further that these statements were made with the knowledge that width made are punishable by fine or imprisorment, or both, under Section 1001 of Title 18 of the United States statements may be proporate the validity of the application or any patent issued thereon.	folso statements and the like on
The undersigned is an attorney or agent of record. Reg. No. 28,075	
John Engelson Signature	MARCH 28,2008
	Date
John H. Engelmann Typed or printed name	
	269-833-2532
7	Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information at be included on this form. Provide credit card information and authorization on PT	nould not 'O-2038.
Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner), orm PTO/SB/66 may be used for making this statement. See MPEP § 324.	which is to file (and by the USPTO

to process an agolication. Confidentially is governed by 35 U.S. 122 and 37 CFR 1.11 and 1.14 This collection is estimated to take 7 one of the Vision general grant substantially in completed application from the U.SFT. This will know glossy upon the individual case. Any comments on the U.SFT. This will know glossy upon the individual case. Any comments on the substantial control of this jou require to complete the form addor suggestions for reducing this burdon, should be sent to the Child from addor suggestions for reducing this burdon, should be sent to the Child from addor suggestions for reducing this burdon, should be sent to the Child from addor suggestions for reducing this burdon, should be sent to the Child from addor suggestions for reducing this burdon, should be sent to the Child from addor suggestions for reducing this burdon, should be sent to the Child from addor suggestions for reducing this suggestion is reducing the suggestion for this suggestion for the child suggestion for the suggest

Confirmation No. 5036

PTC/SB/25 (01-08)

Approved for use through 01/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) PC27932A	
RESECTION OVER A PENDING REPERCINCE APPEICATION	r OZI BOZA	
in re Application of, Nancy J. Britten et al.		
Application No.: 10/803,146		
Filed: March 17, 2004		
For: DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT		
The owner! "Pharmacia & Uploth Company" of 100 percent interest in the instant application which would be except as provided below. The terminal part of the statutory term of any patent granted on the instant application which would excent deeped the expiration date of the full statutory term of any patent granted on pending reference Application Number 10903.680 and of the control of the provided on the rest defined on 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby aspects that any patents or granted on the instant application and years the control of the provided on the reference application are commonly owned. This agreement runs with any patent or particular and years the full provided on the instant application and is bending upon the granted on the instant application and is bending upon the granted. It is useed to the provided of the state of the provided of the provided of the state of the provided of the state of the provided of the provided of the state of the provided of the state of the provided of the state of the provided of t		
In making the above discisitiner, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the explaint of the explaint of the patent granted on said reference application, as the term of any patent granted on said reference application, as the term of any patent granted on said reference application, as the term of any patent granted on said reference application, as the term of any patent granted on the pending reference application, and the patent on the pending reference application, and only the patent granted on the pending reference application, and results of the patent granted on the pending reference application, and results of control to pay a marketerance lose, is find unmediceable, is demind revisible to pay a marketerance lose, is find unmediceable, and revisible to the patent of the patent of the district of the patent of the solution of the substitution of the district of the solution of the substitution of the district of the patent of the substitution than as shortened by any terminal disclaimer filed prior to its grant.		
Check either box 1 or 2 below, if appropriate.		
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, gove etc.), the undersigned is empowered to act on behalf of the business/organization.	mment agency,	
I hereby declare that all statements made herein of my own knowledge are true and that all state belief are believed to be true; and further that these statements were made with the knowledge that willful made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States statements may jeopardize the validity of the application or any patient issued thereon.	false statements and the like so	
2. The undersigned is an attorney or agent of record. Reg. No. 28,075		
John Englinen Signature	MARCH 28, 2008	
	Date	
John H. Engelmann Typed or printed name		
	269-833-2532 Telephone Number	
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner), Form PTO/SBV96 may be used for making this statement. See IMPEP § 324. This collector of information is overpret by 37 CFR 1231 The reformation is exquest to obtain or retain a benefit by the public		
This conscious of incompanion is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public	c writen is to hie (and by the USPTO	

This cuspool of interminating is adjusted by 5° of the latter part of the latter process of the latter process of the latter part of the latter process of

PTO/SB/25 (01-08)

PTO/SE/25 (01-08)
Approved for use through 01/31/2008. OMB 6651-031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

or the Paperwork Reduction Act of 1955, no persons are required to respond to a collection of inform nation unless it displays a valid OMS control number. TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING Docket Number (Ontional) REJECTION OVER A PENDING "REFERENCE" APPLICATION PC279324 In re Application of: Nancy J. Britten et al. Application No.: 10/863 146 Filed: March 17, 2004 For: DISPERSIBLE FORMULATION OF AN ANTHINFLAMMATORY AGENT The owner Pharmacia & Upjohn Company of 100 percent Interest in the instant application hereby disciairs, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/909,050 , filed , as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference on 7/30/2004 application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below if appropriate For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney or agent of record. Reg. No. 28.075 MARCH 28, 200 John H. Engelmann Typed or printed name 269-833-2532 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of formation is required by 37 CFR 1321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO INC.) and the public which is to file (and by the USPTO INC.) and the public which is to file (and by the USPTO INC.) and the public which is to governed by 39 US C 122 and 37 CFR 113 and 14. This collection is estimated to take 12 minutes to complete including pullering, preparing, and the product of the public which is to find the public which is to find the public which is to fin

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.